Division of Cardiology Department of Medicine University of Verona Italy.
J Am Heart Assoc. 2020 Aug 18;9(16):e017194. doi: 10.1161/JAHA.120.017194. Epub 2020 Aug 13.
Background Differences in the impact of contrast medium on the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing transcatheter aortic valve implantation (TAVI) or a coronary angiography/percutaneous coronary intervention (CA/PCI) have not been previously investigated. Methods and Results Patients treated with TAVI or elective CA/PCI were retrospectively analyzed in terms of baseline and procedural characteristics, including preprocedural and postprocedural kidney function. CI-AKI was defined as a relative increase in serum creatinine concentration of at least 0.3 mg/dL within 72 hours of contrast-medium administration compared with baseline. The incidence of CI-AKI in the TAVI versus CA/PCI group was compared. After the exclusion of patients in dialysis and emergency procedures, 977 patients were analyzed; there were 489 patients who had undergone TAVI (50.1%) and 488 patients who had undergone CA/PCI (49.9%). Patients treated by TAVI were older, presenting a higher rate of anemia and chronic kidney disease (<0.001 for all comparisons). Consistently, they also had a significantly lower glomerular filtration rate and higher serum creatinine concentration (<0.001 for all). However, the occurrence of CI-AKI was significantly lower in these patients compared with patients treated by a CA/PCI (6.7% versus 14.5%, <0.001). At multivariate analysis, the TAVI procedure had an independent protective effect on CI-AKI incidence among total population (odds ratio, 0.334; 95% CI, 0.193-0.579; <0.001). This observation was confirmed after propensity score matching among 360 patients (180 by TAVI and 180 by CA/PCI; =0.002). Conclusions CI-AKI occurred less frequently in patients undergoing TAVI than in patients undergoing a CA/PCI, despite a worse-risk profile. The impact of contrast administration on kidney function in patients who had undergone TAVI may be better tolerated because of the hemodynamic changes following aortic valve replacement.
经导管主动脉瓣植入术(TAVI)或冠状动脉造影/经皮冠状动脉介入治疗(CA/PCI)患者对比剂对对比剂诱导的急性肾损伤(CI-AKI)发展的影响存在差异,但尚未得到研究。
回顾性分析了接受 TAVI 或择期 CA/PCI 治疗的患者的基线和手术特征,包括术前和术后肾功能。CI-AKI 定义为与基线相比,对比剂给药后 72 小时内血清肌酐浓度至少升高 0.3mg/dL。比较 TAVI 组与 CA/PCI 组的 CI-AKI 发生率。排除透析和急诊患者后,分析了 977 例患者;其中 489 例患者接受 TAVI(50.1%),488 例患者接受 CA/PCI(49.9%)。接受 TAVI 治疗的患者年龄较大,贫血和慢性肾脏病的发生率较高(所有比较均<0.001)。一致地,他们的肾小球滤过率也明显较低,血清肌酐浓度较高(所有比较均<0.001)。然而,与接受 CA/PCI 治疗的患者相比,这些患者的 CI-AKI 发生率明显较低(6.7%与 14.5%,<0.001)。多变量分析显示,TAVI 术在总人群中对 CI-AKI 发生率具有独立的保护作用(比值比,0.334;95%置信区间,0.193-0.579;<0.001)。在 360 例患者中进行倾向评分匹配后(180 例接受 TAVI 治疗,180 例接受 CA/PCI 治疗;=0.002),观察结果得到了证实。
尽管风险状况较差,但与接受 CA/PCI 治疗的患者相比,接受 TAVI 治疗的患者发生 CI-AKI 的频率较低。主动脉瓣置换术后血流动力学变化可能使 TAVI 患者对对比剂对肾功能的影响具有更好的耐受性。